MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Revance Therapeutics Operating Income 2011-2026 | RVNC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Revance Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -317 M | -342 M | -275 M | -273 M | -164 M | -143 M | -120 M | -88.2 M | -72.3 M | -52 M | -38.2 M | -43.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -38.2 M | -342 M | -161 M |
Quarterly Operating Income Revance Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.3 M | -34.5 M | -46.8 M | - | -37.6 M | -56.3 M | -46.7 M | - | -77.5 M | -57.8 M | -62.2 M | - | -72.7 M | -70.3 M | -70 M | - | -77.1 M | -57.1 M | -61 M | -46.2 M | -42.5 M | -39.1 M | -36.6 M | -38.4 M | -33.6 M | -34.9 M | -35.7 M | - | -30.7 M | -26.8 M | -27.1 M | - | -17.7 M | -24.1 M | -19.7 M | - | -18.8 M | -16.6 M | -15.2 M | - | -13.8 M | -12.9 M | -11.5 M | - | -8.27 M | -11.3 M | -9.68 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.27 M | -77.5 M | -37.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.36 | -2.52 % | $ 362 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
DBV Technologies S.A.
DBVT
|
-147 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Dyadic International
DYAI
|
-7.19 M | $ 0.87 | 0.59 % | $ 31.5 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.6 | -2.26 % | $ 16.3 M | USA |
 |
Fate Therapeutics
FATE
|
-148 M | $ 1.14 | -4.2 % | $ 135 M | USA |
 |
Forte Biosciences
FBRX
|
-70.7 M | $ 26.44 | - | $ 342 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 6.16 | -4.05 % | $ 176 M | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Amicus Therapeutics
FOLD
|
32.8 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-84.8 M | $ 7.57 | -3.32 % | $ 480 K | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.28 | -11.13 % | $ 146 M | USA |
 |
Gilead Sciences
GILD
|
10 B | $ 138.34 | -1.28 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 0.54 | 4.28 % | $ 503 K |  Israel |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 27.14 | -2.2 % | $ 17 B |  Danmark |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
15.3 B | $ 88.2 | -3.37 % | $ 27.2 B | Germany |
 |
Gossamer Bio
GOSS
|
-171 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.62 | -3.29 % | $ 190 M | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 7.98 | -3.04 % | $ 6.83 B |  Spain |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 0.41 | -8.56 % | $ 2.26 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 316.69 | -4.13 % | $ 41.5 B | USA |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 63.72 | 1.01 % | $ 7.64 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 27.53 | -0.67 % | $ 1.58 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.53 | 1.0 % | $ 726 M | Britain |